BCYC
Price
$8.70
Change
+$0.20 (+2.35%)
Updated
Jun 6, 04:09 PM (EDT)
Capitalization
589.35M
55 days until earnings call
XNCR
Price
$9.43
Change
+$0.31 (+3.40%)
Updated
Jun 6, 11:34 AM (EDT)
Capitalization
649.08M
54 days until earnings call
Interact to see
Advertisement

BCYC vs XNCR

Header iconBCYC vs XNCR Comparison
Open Charts BCYC vs XNCRBanner chart's image
Bicycle Therapeutics
Price$8.70
Change+$0.20 (+2.35%)
Volume$786
Capitalization589.35M
Xencor
Price$9.43
Change+$0.31 (+3.40%)
Volume$520
Capitalization649.08M
BCYC vs XNCR Comparison Chart
Loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. XNCR commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Buy and XNCR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (BCYC: $8.51 vs. XNCR: $9.12)
Brand notoriety: BCYC and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 55% vs. XNCR: 55%
Market capitalization -- BCYC: $589.35M vs. XNCR: $649.08M
BCYC [@Biotechnology] is valued at $589.35M. XNCR’s [@Biotechnology] market capitalization is $649.08M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, both BCYC and XNCR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 6 TA indicator(s) are bullish while XNCR’s TA Score has 4 bullish TA indicator(s).

  • BCYC’s TA Score: 6 bullish, 2 bearish.
  • XNCR’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, BCYC is a better buy in the short-term than XNCR.

Price Growth

BCYC (@Biotechnology) experienced а -2.18% price change this week, while XNCR (@Biotechnology) price change was +17.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.55%. For the same industry, the average monthly price growth was +17.24%, and the average quarterly price growth was +3.49%.

Reported Earning Dates

BCYC is expected to report earnings on Jul 31, 2025.

XNCR is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+11.55% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XNCR($649M) has a higher market cap than BCYC($589M). BCYC YTD gains are higher at: -39.214 vs. XNCR (-60.313). XNCR has higher annual earnings (EBITDA): -161.68M vs. BCYC (-200.61M). BCYC has more cash in the bank: 793M vs. XNCR (470M). BCYC has less debt than XNCR: BCYC (8.33M) vs XNCR (67.8M). XNCR has higher revenues than BCYC: XNCR (127M) vs BCYC (25.7M).
BCYCXNCRBCYC / XNCR
Capitalization589M649M91%
EBITDA-200.61M-161.68M124%
Gain YTD-39.214-60.31365%
P/E RatioN/AN/A-
Revenue25.7M127M20%
Total Cash793M470M169%
Total Debt8.33M67.8M12%
FUNDAMENTALS RATINGS
BCYC vs XNCR: Fundamental Ratings
BCYC
XNCR
OUTLOOK RATING
1..100
149
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
78
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9094
PRICE GROWTH RATING
1..100
9093
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
3450

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (22) in the null industry is somewhat better than the same rating for XNCR (78) in the Biotechnology industry. This means that BCYC’s stock grew somewhat faster than XNCR’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as XNCR (100) in the Biotechnology industry. This means that BCYC’s stock grew similarly to XNCR’s over the last 12 months.

BCYC's SMR Rating (90) in the null industry is in the same range as XNCR (94) in the Biotechnology industry. This means that BCYC’s stock grew similarly to XNCR’s over the last 12 months.

BCYC's Price Growth Rating (90) in the null industry is in the same range as XNCR (93) in the Biotechnology industry. This means that BCYC’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for BCYC (100) in the null industry. This means that XNCR’s stock grew significantly faster than BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCXNCR
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
62%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
72%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 4 days ago
72%
Declines
ODDS (%)
Bearish Trend 17 days ago
87%
Bearish Trend about 1 month ago
80%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
69%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MEMIX38.73N/A
N/A
MFS Emerging Markets Equity I
TFIFX44.42N/A
N/A
T. Rowe Price Financial Services I
GSACX19.37N/A
N/A
Goldman Sachs China Equity C
IPOIX20.87N/A
N/A
Macquarie Systematic Em Mkts Eq I
VBPIX21.55N/A
N/A
Vanguard Baillie GiffordGlbPstvImpStkInv

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with INO. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+0.59%
INO - BCYC
57%
Loosely correlated
N/A
XNCR - BCYC
54%
Loosely correlated
+0.22%
RLAY - BCYC
51%
Loosely correlated
N/A
RPTX - BCYC
51%
Loosely correlated
+2.76%
RCUS - BCYC
45%
Loosely correlated
+0.31%
More

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with CRNX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
+0.22%
CRNX - XNCR
58%
Loosely correlated
+0.59%
BEAM - XNCR
56%
Loosely correlated
-0.87%
ERAS - XNCR
55%
Loosely correlated
+2.61%
BCYC - XNCR
54%
Loosely correlated
+0.59%
CGON - XNCR
54%
Loosely correlated
+0.23%
More